Targeted Screening for Taenia Solium Tapeworms

NCT ID: NCT01296958

Last Updated: 2014-10-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1811 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether screening and treatment of tapeworm carriers can decrease community transmission of Taenia solium parasitic infection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Taenia Solium Taeniasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Targeted screening

Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.

Group Type EXPERIMENTAL

Niclosamide

Intervention Type DRUG

Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)

Education

Community education about Taenia solium prevention.

Group Type ACTIVE_COMPARATOR

Community education campaign

Intervention Type BEHAVIORAL

Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Niclosamide

Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)

Intervention Type DRUG

Community education campaign

Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All community members are eligible

Exclusion Criteria

* Inability to provide informed consent
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National University of San Marcos, Peru

OTHER

Sponsor Role collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

Oregon Health and Science University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Seth E O'Neal, MD MPH

Assistant professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Seth E ONeal, MD MPH

Role: PRINCIPAL_INVESTIGATOR

Oregon Health and Science University

Armando Gonzalez, DVM PhD

Role: PRINCIPAL_INVESTIGATOR

San Marcos University School of Veterinary Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

San Marcos University

Lima, , Peru

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Peru

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R21NS069275-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R21NS069275-01

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ivermectin and Human Immunity
NCT03459794 COMPLETED EARLY_PHASE1
Nepal Elimination of Trachoma Study
NCT02176057 WITHDRAWN PHASE2/PHASE3